Sermorelin

Sermorelin acetate, also called GHRH 1-29, synthetically reproduces the first 29 amino acids of the body’s growth hormone-releasing hormone. It prompts pituitary cells to make and release their own growth hormone, preserving a physiological pattern of secretion instead of providing external HGH. Geref previously had FDA approvals for diagnosing and treating growth hormone deficiency; both approvals were withdrawn on 2009-06-18 after discontinuation in 2008. FDA later determined that safety or effectiveness was not the reason for withdrawal. Prescription access through compounding and telehealth does not reinstate those product approvals.

• Growth Hormone Support

  Most effective

  Pituitary signaling stimulates the release of growth hormone made within the body.

• Body Composition

  Effective

  Research associates use with greater lean mass and a reduction in body fat.

• Recovery & Repair

  Effective

  Investigation concerns tissue repair and recovery after exercise or injury.

• Sleep Quality

  Moderate

  Some research schedules are associated with better restorative sleep and slow-wave sleep.

These are commonly discussed research protocols — not medical advice. Consult a healthcare provider before use.

• Insulin / IGF-1

  Monitor

• Corticosteroids

  Caution

• Thyroid Hormones

  Monitor

• BPC-157

  Compatible

• TB-500

  Compatible

• Ipamorelin + CJC-1295

  Compatible

  Proposed complementary activity is the rationale for combining these compounds.

• Somatostatin Analogs

  Avoid

Diluent: Use only bacteriostatic water; avoid saline because precipitation can occur.

1. Let your refrigerated Sermorelin vial stand for 15–20 minutes so it reaches room temperature before mixing.
2. Disinfect the rubber stopper using an alcohol swab. Wait for all of the alcohol to air-dry.
3. Measure the calculated bacteriostatic water volume with a sterile syringe. Use BAC water only; saline can lead to precipitation.
4. Deliver the water slowly against the vial’s inner wall. Keep the stream from striking the powder directly.
5. Mix by gently rotating the vial in circles. Avoid vigorous shaking, which can break down the peptide.
6. Wait 2–3 minutes until dissolution is complete. Inspect the liquid for a clear appearance without color.
7. Measure your calculated dose in an insulin syringe for administration beneath the skin.
8. Choose your abdomen, upper arm or thigh for subcutaneous administration. Change sites between injections to help prevent lipodystrophy.
9. Keep the mixed vial at 2–8 °C in the refrigerator. Use the solution within 28 days of preparation.

Week 1–2

Sleep quality may start to improve, with mild fluid retention possible during early adjustment.

Week 2–4

Deeper sleep and better recovery may emerge; a small increase in appetite can accompany them.

Week 4–8

Changes in energy, body composition and the speed of recovery may become more apparent.

Week 8–12

Improved skin quality, less body fat and a visible increase in lean mass may develop.

Week 12+

Later expectations include continued improvements in strength, body composition and vitality; individual outcomes are not assured.

• Fluid retention with mild bloating, particularly near the beginning
• Greater appetite, especially alongside GHRP compounds
• Warmth or flushing around the injection area
• Numbness or tingling, including carpal-tunnel-like symptoms with higher doses
• Lethargy or tiredness when timing is suboptimal
• Possible increases in prolactin and cortisol, especially with GHRP-6
• Higher blood glucose; monitor glucose if you have diabetes or prediabetes · Rare

Sermorelin: withdrawn in the US.

• US

  Withdrawn

  FDA — Geref (sermorelin acetate): NDA 20-443 (0.5 and 1.0 mg vials) for idiopathic growth hormone deficiency in children with growth failure, NDA 19-863 (0.05 mg ampoule) for evaluating pituitary growth-hormone secretion; discontinued 2008, approvals withdrawn 2009-06-18 (not for safety or effectiveness reasons)

  Rx required

  Yes

  Telehealth

  Available

  Checked on

  15 Sept 2026

1. Growth hormone-releasing peptides: clinical applications (2008)

2. Growth hormone releasing hormone. (1986)

   PMID 2429796DOI 10.1016/s0300-595x(86)80012-3

3. GEREF (sermorelin acetate) for injection - Prescribing Information (1997)

4. Sermorelin studies on ClinicalTrials.gov (2024)